17,031 Shares of Charles River Laboratories International, Inc. $CRL Bought by CenterBook Partners LP

CenterBook Partners LP purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the third quarter, Holdings Channel.com reports. The fund purchased 17,031 shares of the medical research company’s stock, valued at approximately $5,024,000.

Other hedge funds have also recently modified their holdings of the company. Physician Wealth Advisors Inc. raised its position in shares of Charles River Laboratories International by 127.9% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 55 shares during the last quarter. Continuum Advisory LLC acquired a new stake in Charles River Laboratories International in the 2nd quarter worth approximately $30,000. IFP Advisors Inc boosted its stake in Charles River Laboratories International by 182.8% in the 3rd quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock worth $48,000 after purchasing an additional 106 shares in the last quarter. Compass Wealth Management LLC purchased a new stake in Charles River Laboratories International during the 3rd quarter worth approximately $69,000. Finally, Activest Wealth Management grew its position in Charles River Laboratories International by 25.9% during the 3rd quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after purchasing an additional 57 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft upped their price target on shares of Charles River Laboratories International from $300.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, September 25th. CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective for the company. in a research note on Monday, July 20th. Argus set a $330.00 price objective on shares of Charles River Laboratories International in a report on Thursday, September 17th. Piper Sandler set a $300.00 target price on Charles River Laboratories International in a research report on Monday, August 10th. Finally, Robert W. Baird raised their target price on Charles River Laboratories International from $291.00 to $334.00 and gave the stock an “outperform” rating in a research note on Friday, September 25th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average price target of $308.17.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $337.91 on Friday. The firm has a market capitalization of $16.19 billion, a P/E ratio of 371.33, a PEG ratio of 3.14 and a beta of 1.36. The stock has a 50-day simple moving average of $305.71 and a two-hundred day simple moving average of $225.19. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.04 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a fifty-two week low of $146.20 and a fifty-two week high of $379.63.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $0.12. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The firm had revenue of $982.73 million for the quarter, compared to the consensus estimate of $960.36 million. During the same quarter in the prior year, the business earned $2.43 earnings per share. The company’s revenue was down 2.2% compared to the same quarter last year. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.44 earnings per share for the current year.

Insider Buying and Selling

In other Charles River Laboratories International news, CEO Birgit Girshick sold 6,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the sale, the chief executive officer owned 36,013 shares in the company, valued at approximately $10,080,038.70. This represents a 15.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 3,714 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.66, for a total transaction of $1,038,657.24. Following the sale, the executive vice president directly owned 4,807 shares in the company, valued at $1,344,325.62. The trade was a 43.59% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 102,299 shares of company stock valued at $31,050,863 in the last ninety days. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support.

The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions.